FocalTherics $FOCL Shares Purchased by Rock Springs Capital Management LP

Rock Springs Capital Management LP raised its position in FocalTherics (NASDAQ:FOCL) by 7.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,378,000 shares of the company’s stock after acquiring an additional 91,500 shares during the quarter. Rock Springs Capital Management LP owned approximately 3.68% of FocalTherics worth $5,126,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Flax Pond Capital LLC acquired a new stake in shares of FocalTherics in the 4th quarter valued at $2,623,000. SmartHarvest Portfolios LLC acquired a new position in shares of FocalTherics during the first quarter worth $38,000. Lido Advisors LLC acquired a new position in shares of FocalTherics during the first quarter worth $40,000. Kovack Advisors Inc. purchased a new position in FocalTherics in the fourth quarter valued at $53,000. Finally, Leonteq Securities AG purchased a new position in FocalTherics in the fourth quarter valued at $313,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on FOCL shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. Mizuho set a $15.00 price objective on FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.00.

Insider Transactions at FocalTherics

In other news, Director Joshua Levine purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $4.22 per share, for a total transaction of $42,200.00. Following the purchase, the director directly owned 35,000 shares of the company’s stock, valued at $147,700. This represents a 40.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.10% of the stock is owned by corporate insiders.

FocalTherics Price Performance

Shares of FOCL opened at $6.15 on Tuesday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. FocalTherics has a 1-year low of $1.21 and a 1-year high of $6.18. The firm has a market capitalization of $230.50 million, a P/E ratio of -7.59 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%.The firm had revenue of $20.48 million for the quarter, compared to analysts’ expectations of $19.46 million. As a group, equities analysts expect that FocalTherics will post -0.78 EPS for the current fiscal year.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.